(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/096637 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *C07D 487/10* (2006.01)
C07D 401/14 (2006.01) *C07D 491/10* (2006.01)
C07D 403/12 (2006.01) *C07D 498/10* (2006.01)
C07D 417/12 (2006.01) *A61P 29/00* (2006.01)
C07D 417/14 (2006.01) *A61K 31/4439* (2006.01)

(21) International Application Number:
PCT/US2024/053696

(22) International Filing Date:
30 October 2024 (30.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/594,859 31 October 2023 (31.10.2023) US
63/650,744 22 May 2024 (22.05.2024) US

(71) Applicant: **XENON PHARMACEUTICALS INC.** [CA/CA]; 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(72) Inventor; and
(71) Applicant: **BOYD, Michael J.** [US/US]; 33 Lantern Ln., Sharon, Massachusetts 02067 (US).

(72) Inventors: **CHARIFSON, Paul S.**; 5004 Mountain View Rd., Carrabassett Valley, Maine 04947 (US). **CLARK, Michael Philip**; 30 Kenney Lane, Concord, Massachusetts 01742 (US). **GILBERT, James**; 36 Monroe St., Norwood, Massachusetts 02062 (US). **JACKSON, Stephen**; 401-2288 Alpha Ave., Burnaby, British Columbia V5C 0L9 (CA). **HAMBIRA, Chido M.**; 51 East 46th Ave., Vancouver, British Columbia V5W 1Z2 (CA). **BURFORD, Kristen**; 5138 McHardy Street, Vancouver, British Columbia V5R 0K7 (CA). **CLEMENT, Helen**; 305-5087 Irving Street, Burnaby, British Columbia V5H 1T6 (CA). **KIM, Jung Yun**; 2418 W 36th Avenue, Vancouver, British Columbia V6M 1L6 (CA). **LOFSTRAND, Verner Alexander**; 6404 Buckingham Drive, Burnaby, British Columbia V5E 3Y6 (CA).

(74) Agent: **COVERT, John M.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1101 K Street NW, 10th Floor, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/096637 A1

(54) Title: SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS



I

(57) Abstract: The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts, solvates, and stereoisomers thereof, wherein M^1, M^2, M^3, M^4, Z, n, R^5, R^6, W, A, and R^9 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to inhibit sodium channels (e.g., Nav1.7) and/or to treat a disorder responsive to the inhibition of a sodium channel (e.g., Nav1.7). Compounds of the present disclosure may be useful for treating pain.